Home › Research › Down syndrome and Alzheimer's
Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial
Cooper SA, Ademola T, Caslake M, Douglas E, Evans J, Greenlaw N, Haig C, Hassiotis A et al.. Trials, 2016-07-29
Topic: Risk, prevention and care in population studies
Plain-language summary
Methods TOP-COG was a feasibility/pilot, double-blind RCT of 12 months simvastatin 40 mg versus placebo for the primary prevention of dementia in Alzheimer disease in Down syndrome adults aged 50 years or older. Results were analysed on an intention-to-treat basis. Results We identified 181 (78 %) of the likely eligible Down syndrome population, and recruited 21 (11.6 %), from an area with a general population size of 3,135,974. Aβ40 levels changed less for the simvastatin group (not statistically significant).
What this study adds
Evidence grade: High
This is a follow-up (cohort) study of 21 participants. This pilot trial of simvastatin 40 mg versus placebo in adults with Down syndrome aged 50 or older recruited only 21 people and found that Aβ40 levels changed less for the simvastatin group, which was not statistically significant. As a small feasibility study, it does not show that simvastatin prevents dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cooper, S. A., Ademola, T., Caslake, M., Douglas, E., Evans, J., Greenlaw, N., et al. (2016). Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial. Trials. https://doi.org/10.1186/s13063-016-1370-9
Vancouver
Cooper SA, Ademola T, Caslake M, Douglas E, Evans J, Greenlaw N, et al. Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial. Trials. 2016. doi:10.1186/s13063-016-1370-9. PMID: 27473843.
BibTeX
@article{cooper2016-27473843,
author = {Cooper, S. A. and Ademola, T. and Caslake, M. and Douglas, E. and Evans, J. and Greenlaw, N. and Haig, C. and Hassiotis, A. and others},
title = {{Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial}},
journal = {Trials},
year = {2016},
doi = {10.1186/s13063-016-1370-9},
pmid = {27473843},
url = {https://doi.org/10.1186/s13063-016-1370-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Methods TOP-COG was a feasibility/pilot, double-blind RCT of 12 months simvastatin 40 mg versus placebo for the primary prevention of dementia in Alzheimer disease in Down syndrome adults aged 50 years or older.
- Results were analysed on an intention-to-treat basis.
- Results We identified 181 (78 %) of the likely eligible Down syndrome population, and recruited 21 (11.6 %), from an area with a general population size of 3,135,974.
- Aβ40 levels changed less for the simvastatin group (not statistically significant).
Why it matters
This pilot trial of simvastatin 40 mg versus placebo in adults with Down syndrome aged 50 or older recruited only 21 people and found that Aβ40 levels changed less for the simvastatin group, which was not statistically significant. As a small feasibility study, it does not show that simvastatin prevents dementia.
Study details
- Study designcohort study
- Participants21
- Evidence strengthHigh
How this study scored 60/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Trials) |
| Journal's citation record | 1 / 4 | Trials: journal h-index 132 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 21 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 3 / 7 | Cited 27 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.2 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 2 / 6 | Cited 2.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Frank Sullivan: h-index 70 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27473843) |
| Free to read | 2 / 2 | Free to read |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.